Braveheart Bio, Inc. [BRVE] - IPO
Braveheart Bio, Inc. is offering 21,250,000 shares of common stock at an initial public offering price of $18.00 per share, aiming for total gross proceeds of $382,500,000 before underwriting discounts and commissions.
Why this matters
Braveheart Bio, Inc., a pharmaceutical company based in Delaware, specializes in developing innovative treatments within the pharmaceutical preparations industry. The company is coming to market with an initial public offering of 21,250,000 shares of common stock priced at $18.00 per share, aiming to raise approximately $382,500,000 in gross proceeds before underwriting discounts and commissions. This IPO is structured to enhance the company's financial capacity, potentially supporting its ongoing research and development initiatives.